These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 18210050)

  • 1. [Fumaric acid and its esters in the treatment of multiple sclerosis: studies and effects].
    Stangel M; Moharregh-Khiabani D; Linker RA; Gold R
    Nervenarzt; 2008 Feb; 79(2):212-7. PubMed ID: 18210050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fumarates for the treatment of multiple sclerosis: potential mechanisms of action and clinical studies.
    Linker RA; Lee DH; Stangel M; Gold R
    Expert Rev Neurother; 2008 Nov; 8(11):1683-90. PubMed ID: 18986239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of oxidative damage in multiple sclerosis and neurodegenerative diseases: therapeutic modulation via fumaric acid esters.
    Lee DH; Gold R; Linker RA
    Int J Mol Sci; 2012; 13(9):11783-11803. PubMed ID: 23109883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances in the biomedical applications of fumaric acid and its ester derivatives: The multifaceted alternative therapeutics.
    Das RK; Brar SK; Verma M
    Pharmacol Rep; 2016 Apr; 68(2):404-14. PubMed ID: 26922546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving the Gastrointestinal Tolerability of Fumaric Acid Esters: Early Findings on Gastrointestinal Events with Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis from the Phase 3, Open-Label EVOLVE-MS-1 Study.
    Palte MJ; Wehr A; Tawa M; Perkin K; Leigh-Pemberton R; Hanna J; Miller C; Penner N
    Adv Ther; 2019 Nov; 36(11):3154-3165. PubMed ID: 31538304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dimethyl fumarate (BG-12) for the treatment of multiple sclerosis.
    Stangel M; Linker RA
    Expert Rev Clin Pharmacol; 2013 Jul; 6(4):355-62. PubMed ID: 23927662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spotlight on fumarates.
    Lee DH; Linker RA; Gold R
    Int MS J; 2008 Mar; 15(1):12-8. PubMed ID: 18713564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fumaric Acid and its esters: an emerging treatment for multiple sclerosis.
    Moharregh-Khiabani D; Linker RA; Gold R; Stangel M
    Curr Neuropharmacol; 2009 Mar; 7(1):60-4. PubMed ID: 19721818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fumaric acid and its esters: an emerging treatment for multiple sclerosis with antioxidative mechanism of action.
    Gold R; Linker RA; Stangel M
    Clin Immunol; 2012 Jan; 142(1):44-8. PubMed ID: 21414846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fumaric acid esters in psoriasis and multiple sclerosis.
    Zecca C; Caporro M; Adami M; Mainetti C; Gobbi C
    Clin Exp Dermatol; 2014 Jun; 39(4):488-91. PubMed ID: 24779791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dimethyl fumarate for multiple sclerosis.
    Papadopoulou A; D'Souza M; Kappos L; Yaldizli O
    Expert Opin Investig Drugs; 2010 Dec; 19(12):1603-12. PubMed ID: 21067468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple sclerosis: oral BG12 for treatment of relapsing-remitting MS.
    Limmroth V
    Nat Rev Neurol; 2013 Jan; 9(1):8-10. PubMed ID: 23147843
    [No Abstract]   [Full Text] [Related]  

  • 13. Oral BG-12 (dimethyl fumarate) for relapsing-remitting multiple sclerosis: a review of DEFINE and CONFIRM. Evaluation of: Gold R, Kappos L, Arnold D, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012;367:1098-107; and Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012;367:1087-97.
    Havrdova E; Hutchinson M; Kurukulasuriya NC; Raghupathi K; Sweetser MT; Dawson KT; Gold R
    Expert Opin Pharmacother; 2013 Oct; 14(15):2145-56. PubMed ID: 23971970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dimethyl fumarate for treating relapsing multiple sclerosis.
    Sheremata W; Brown AD; Rammohan KW
    Expert Opin Drug Saf; 2015 Jan; 14(1):161-70. PubMed ID: 25382392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Extending therapeutic possibilities in relapsing-remitting multiple sclerosis: dimethyl fumarate].
    Matolcsi J; Rózsa C
    Ideggyogy Sz; 2015 Jan; 68(1-2):7-14. PubMed ID: 25842911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration.
    Schilling S; Goelz S; Linker R; Luehder F; Gold R
    Clin Exp Immunol; 2006 Jul; 145(1):101-7. PubMed ID: 16792679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The fumaric acid ester BG-12: a new option in MS therapy.
    Lee DH; Stangel M; Gold R; Linker RA
    Expert Rev Neurother; 2013 Aug; 13(8):951-8. PubMed ID: 23944289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dimethyl fumarate: a review of its use in patients with relapsing-remitting multiple sclerosis.
    Burness CB; Deeks ED
    CNS Drugs; 2014 Apr; 28(4):373-87. PubMed ID: 24623127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dimethyl fumarate for treatment of multiple sclerosis: mechanism of action, effectiveness, and side effects.
    Linker RA; Gold R
    Curr Neurol Neurosci Rep; 2013 Nov; 13(11):394. PubMed ID: 24061646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: the DEFINE study.
    Kappos L; Gold R; Arnold DL; Bar-Or A; Giovannoni G; Selmaj K; Sarda SP; Agarwal S; Zhang A; Sheikh SI; Seidman E; Dawson KT
    Mult Scler; 2014 Feb; 20(2):243-52. PubMed ID: 24150779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.